Articles

Poll

Podcasts

Slideshows

Videos

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

New ACG 2024 data show patients with both IBD and vitamin D deficiency face longer, more expensive hospital stays, as well as risk of colectomy.

Vitamin D Deficiency Linked to Worse IBD Hospital Outcomes

Banty discusses recent advancements in the ulcerative colitis and Crohn disease treatment landscapes, explaining how to navigate the growing number of treatment options.

Andrea Banty, NP, DNP: Navigating New Developments in IBD Therapeutics

Solomon explains how to navigate the growing Crohn disease treatment armamentarium and the importance of treatment positioning.

Positioning Medications in Crohn Disease, with Teddy Solomon, MSN, NP

The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.

FDA Approves Guselkumab (Tremfya) for Ulcerative Colitis

The HCPLive August gastroenterology month in review spotlights expansions in gastrointestinal treatment and screening access as well as the newest edition of Qazi Corner.

Gastroenterology Month in Review: August 2024

AHN Division of Gastroenterology, Hepatology, and Nutrition addresses patients’ challenging symptoms and needs with wide-ranging strategies and innovative treatments.

AHN Unraveling the Complexities of IBD with Innovations in Diagnosis and Management  

Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD, conclude by sharing their approaches to evaluating patient satisfaction and expectations when providing care for ulcerative colitis and Crohn's disease, while also touching upon the importance of discussing the potential need for escalating or switching therapies to better manage the underlying disease processes. 

Measuring Patient Satisfaction with Inflammatory Bowel Disease Treatments and Communication Regarding Treatment Changes 

Jean-Frederic Colombel, MD, examines considerations for transitioning patients from intravenous to subcutaneous infliximab and evaluates the role of subcutaneous infliximab within the evolving landscape of inflammatory bowel disease treatments. 

Patient Selection and Switching Patients to Subcutaneous Infliximab

A key opinion leader analyzes the clinical remission and endoscopic response data from the LIBERTY CD and LIBERTY UC trials for subcutaneous infliximab-dyyb injection, contrasts it with intravenous infliximab, and evaluates the drug's safety and efficacy profile. 

Efficacy and Safety of Subcutaneous Infliximab  

Jean-Frederic Colombel, MD, offers insights into subcutaneous infliximab-dyyb injection, detailing its administration and approved indications for ulcerative colitis and Crohn's disease. 

Reducing Treatment Burden in IBD with At-Home Therapy Options

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.